- Home
- SAVA
as 10-24-2025 3:56pm EST
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 213.0M | IPO Year: | N/A |
| Target Price: | $5.00 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $33.98 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cassava Sciences Inc. News
SAVA Breaking Stock News: Dive into SAVA Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
Simply Wall St.
5 months ago
Promising Penny Stocks To Consider In May 2025
GlobeNewswire
6 months ago
Cassava Reports Q1 2025 Financials Results, Provides Business Update
GlobeNewswire
6 months ago
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
MT Newswires
6 months ago
Cassava Sciences CMO James Kupiec to Retire
GlobeNewswire
6 months ago
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
Zacks
7 months ago
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround
Zacks
7 months ago
Is the Future Bleak for SAVA Stock Following Another Setback?
Compare SAVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SAVA Cassava Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.